Health Condition 1: H209- Unspecified iridocyclitis
Conditions
Interventions
Intervention1: Methotrexate, Tofacinitinib: Oral Methotrexate 25mg maximum once a week with folic acid 5mg twice a weekfor minimum 1 year
Oral Tofacitinib 5mg twice a day for minimum 1 year
Control I
Sponsors
Dr. Shroff Charity Eye Hospital
Eligibility
Inclusion criteria
Inclusion criteria: -Treatment Naive HLAB27 positive Uveitis patient with recurrent Uveitis of more than 2 episodes per year with or without articular manifestation. Here Treatment naive means patients who have never been started on any immunosuppressives previously. -Treatment naive HLAB27 positive Uveitis associated with articular manifestations diagnosed using Assessment of Spondyloarthritis International Society classification criteria. -History of topical steroids use or oral steroids use of 4 weeks or less need not be excluded
Exclusion criteria
Exclusion criteria: -People who do not give consent for treatment -Patients not consenting to follow-up visits -Patients non-compliant to treatment -Current or prior treatment with any immunosuppressive agents or biologics -Major side-effects from medicines like raised liver enzymes sgot/sgpt more than 5 times, persistent low TLC count of less than 2500 or any drug intolerance -Patient unfit as deemed by the physician for receiving immunosuppressive therapy -Any active infections in the body -Pregnant female or female planning pregnancy in future.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Defined by quiescence that is absence of inflammatory activity or significant reduction in terms of AC cells, reduced Flare, AVF cells, Disc hyperaemia, CME and/or Vitritis and also no recurrence (which can be defined as absence of cells on 10th and 12th month that are last 2 follow ups)Timepoint: Monthly for 2 visits and then 2 monthly for complete 1 year. Baseline, 1 month, 2 month, 4 month, 6 month, 8 month, 10 month and 12 month. | — |
Secondary
| Measure | Time frame |
|---|---|
| Presence or Absence of Sight threatening complications like BSK, GlaucomaTimepoint: Monthly for 2 visits & then 2 monthly for complete 1 year. Baseline, 1 month, 2 month, 4 month, 6 month, 8 month, 10 month & 12 month. Number of recurrences if present Decrease in articular inflammatory activity according to ASAS criteria | — |
Countries
India
Contacts
Public ContactTanya Jain
Dr. Shroff Charity Eye Hospital, New Delhi
Outcome results
None listed